PBAC's latest decision on Corifollitropin alfa: Recommended with restriction (2013). Considered for Controlled ovarian stimulation for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques, specifically in women undergoing a gonadotrophin releasing hormone antagonist cycle with an antral follicle count of 20 or less.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2010
Submissions
3
2010 → 2013
Eligible population
Women undergoing assisted reproductive technologies (in-vitro fertilisation) with an antral follicle count of 20 or less, undergoing a gonadotrophin releasing hormone antagonist cycle.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Ongoing pregnancy rate
Pivotal trial size
1,390 patients
Key trials
ENGAGE, PURSUE
Comparator
follitropin beta (recombinant FSH)
Economic model
Cost-minimisation
ICER note
cost-minimisation analysis; no ICER calculated as non-inferiority claimed on effectiveness outcome
Submission history
Nov 2010: Not recommended
Jul 2011: Recommended with restriction · Restricted
Mar 2013: Recommended with restriction · Restricted